NeuroPace said a landmark study showed 50% of RNS System patients achieved at least a 62% seizure reduction at six months. The result aligns with prior FDA-revi

NeuroPace said a landmark study showed 50% of RNS System patients achieved at least a 62% seizure reduction at six months. The result aligns with prior FDA-reviewed data and comes as the device sees broader clinical adoption in epilepsy care.